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Recently we described a new elastase inhibitor (skin-derived 
antileukoproteinase, SKALP) that is expressed in psoriatic 
epidermis and cultured keratinocytes, but is virtually absent 
in normal skin. In this study we investigated whether SKALP 
activity could be measured in urine of psoriatic patients and 
healthy controls. We found that urine o~ psoriatic pa~ie.nts 
contained considerable amounts of anti-elastase actlvlty, 
whereas this activity in urine from normals was significantly 
lower. The properties of the urinary anti-elastase activity in 
psoriatic patients were indistinguishable from that of epider-
mal SKALP. It was found to be a cationic, heat-stable protein 
Polymorphonuclear leukocyte (PMN) - derived protein-ases, including elastase, cathepsin G, proteinase III, and collagenase, are known to cause tissue damage by attack-ing a variety of macromolecular substrates [1]. Protein-ase inhibitors, either systemically present (e.g., al-pro-
teinase inhibitor, a2-macroglobulin) or locally synthesized [e.g., 
antileukoprotease (ALP) or secretory leukocyte proteinase inhibitor 
(SLPI)], are able to limit this proteinase action [2 - 4]. Disturbance of 
the local proteinase-anti proteinase balance is associated wi~~ several 
diseases, including pulmonary emphysema [5,6], arthritis [7,8], 
glomerulonephritis [9], cutaneous vasculitis [10], and several bul-
lous dermatoses [11] . Recently we have described a new elastase-
specific proteinase inhibitor (SKALP) that is found inpsoriat~c epi-
dermis and in cultured keratmocytes [12,13]. SKALP IS very sundar 
if not identical to Elafin, a skin-derived elastase inhibitor described 
by others [14,15]' and to an elastase-specific inhibitor from sputum 
[ 16]. We have previously shown that anti-elastase activity can be 
found in scales from va no us dermatoses [ 17]. Normal skm, how-
ever, was found to contain very little, if any, anti-elastase activity 
[12] . Because anti~elastase is found to be inducable in normal skin 
following tape-stnppmg [12,18]' It was concluded that It acts as a 
regulatory mechanism to control elastase-mediated epidermal tissue 
damage. ..... 
In this study we show that unne of psonatlc patients contams 
appreciable amounts of anti-~Iastase acti.vi~, either free or in a latent 
form. This anti-elastase activity was mdlstmgUlshable from SKALP, 
using biochemical and immunologic criteria. 
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with an apparent molecular weight of 11 kDa on sodium 
dodecylsulfate - polyacrylamide gel electrophoresis (SDS-
PAGE), and a K; of approximately 2 X 10-11 M. In addition , 
in Western blotting partially purified inhibitor from urine 
was found to react with a polyclonal anti-SKALP serum. 
SKALP in urine was either present in a free form or in a latent 
form, most likely complexed with elastase. We speculate that 
SKALP in urine of psoriatic patients is derived from the 
epidermis, and that it might serve as a marker for disease 
activity. ] Invest Dermatol 99:3 - 7, 1992 
MATERIALS AND METHODS 
Chemicals Methoxysuccinyl - alanyl- alanyl - prolyl - valyl- 7 -
amino-4-methylcoumarin, was obtained from Bachem, Bubendorf, 
Switzerland. Cetyltrimethylammoniumbromide (CT AB) was ob-
tained from ICI, UK. All reagents for sodium dodecylsulphate poly-
acrylamide gelelectrophoresis (SDS-PAGE) including prestained 
markers, were obtained from Biorad laboratories, Richmond, CA. 
Polybuffer exchanger 94 (PBE 94) was obtained from Pharmacia 
fine Chemicals, Uppsala, Sweden, and polyvinylidenedifluoride 
(PVDF) membrane from Millipore, Etten-Leur, The Netherlands. 
Swine-anti-rabbit peroxidase was obtained from Dakopatts, Co-
penhagen, Denmark. Low molecular weight markers used for SDS-
gels and diaminobenzidine were obtained from Sigma Chemicals, 
St. Louis, MO. 
Sample Collection and Preparation Urine was collected from 
patients with severe psoriasis and volunteers without skin diseases, 
and stored at - 20 0 C. The patient group consisted of 16 men and 17 
women, mean age 45 ± 20 years. The control group consisted of 
seven men and three women, mean age 38 ± 12 years. Urine sam-
ples were assayed for anti-elastase activity as described below. Elas-
tase activity was measured both in untreated urine and urine that had 
been boiled for 2 min. 
For preparative purposes, 40 ml urine was concentrated by vac-
uum evaporation, dialyzed against distilled water, and used for chro-
matographic purification. 
Assay of Elastase and Anti-Elastase Activity Elastase was 
measured according to previously described methods using the 
fluor~genic substrate methoxysuccinyl-alanyl-alanyl-prolyl-valyl-
7-ammo-4-methylcoumarin [9]. Inhibition of elastase activity was 
measured as the percentage inhibition of a standard amount of elas-
tase. A sensitive microassay was used to enable measurement of 
small amounts of inhibitory activity. Briefly, 10 fil of 4 nM leuko-
cyte elastase was mixed with urine sample (10 pI) and incubated at 
3rc for 15 min to allow complexing of enzyme and the inhibiting 
component in the urine. Thereafter, 20 fil of 250 fiM substrate 
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Figure 1. Dilution curves showing the effect of boiling on elastase and 
anti-elastase activity in urine from a psoriatic patient. When untreated urine 
was added to a standard amount of human leukocyte elastase (100% value), 
additional elastase activity was measured (diafllOtlds). Boiling the urine sam-
ples abolished all elastase activity and released inhibitory activity in a time-
dependent manner. Boiling was done for 1, 2, and 8 min, represented by 
stars, triangles, and circles, respectively. Prolonged boiling resulted in a gradual 
decrease of inhibitory activity. 
solution was added and the reaction was allowed to proceed for 15 
min at 37 °C. All components were dissolved in 1 M NaCl, 0.4% 
CT AB, 0.1 M Tris pH 8.5. The incubation was terminated by the 
addition of 1 ml buffer (100 mM NazCO), pH 10.5) and fluores-
cence was measured at 375 nm (excitation) and 440 nm (emission) 
in a Perkin-Elmer LS-5 fluorimeter. Inhibition of elastase activity in 
this assay was calculated as the percentage inhibition of the activity 
of 40 fmol elastase (quantity in the assay). The unit of inhibitory 
activity was defined as the amount required to reduce the elastase 
activity in the assay by 50%. Elastase activity was linear during the 
assay (final substrate concentration 125 11M, of which less than 10% 
is consumed during the 15 min incubation) . For all urine samples a 
dilution curve was made starting from a 1:2 dilution in assaybuffer 
(see also Fig 1). The amount of anti-elastase activity was expressed 
in units. When maximal inhibition was less than 50%, anti-elastase 
activity was considered to be undetectable. Thus the actual detec-
tion limit is 2 units per 10111 of urine. 
Chromatographic Procedures A PBE 94 chromatofocusing 
column (6 X 1.4 em) was equilibrated with 0.025 M ethanolamine 
buffer, pH 9.4 (starting buffer), and I-ml sample of concentrated, 
dialysed urine was applied in starting buffer. After sample applica-
tion the column was washed with 35 ml of starting buffer. As 
previously described, this column can be used as a convenient and 
efficient purification step without the need to generate a pH gra-
dient over the column [13]. SKALP is extremely cationic and elutes 
in the void volume of the column, whereas most other proteins are 
bound. The column was regenerated by 1 M NaC!. 
The eluent was monitored at 280 nm, 2.5-ml fractions were 
collected, and anti-elastase activity in the eluted fractions was mea-
sured as described above, expressed in units inhibitory activity per 
fraction. The fractions with elastase inhibiting activity were further 
concentrated by vacuum evaporation and used for kinetic studies, 
gel permeation chromatography, and SDS-gel electrophoresis. 
Determination of Dissociation Constant K; Kinetic parame-
ters were determined according to the criteria posed by Bieth [19] , 
using active-site titrated leukocyte elastase, which was also used for 
determination of urinary SKALP concentrations. The dissociation 
constant K j was determined by an Easson-Stedman plot based on the 
equation 1/(1 - a) = KJa + EO, where a is the fractional activity 
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(ratio of enzyme activity in the presence and absence of inhibitor), 
EO is the initial enzyme concentration, and I is the inhibitor concen-
tration. The plot ofl/(l - a) versus l/a yields a straight line whose 
slope is K;. 
Determinations were made in 0.1 M Tris, 1 M NaCl, and 0.4% 
cetyltrimethylammonium bromide, pH 8.5, as described before. 
The use of detergent and high salt is a conditio sine qua non, in order 
to prevent nonspecific absorption of inhibitor or enzyme, because 
extremely low concentrations of purified protein are used. 
SDS-PAGE and Western Blotting Fractions with elastase in-
hibiting activity obtained after chromatofocusing were pooled, 
concentrated by vacuum evaporation, and subjected to SDS-P AGE 
(non-reducing conditions). Proteins were separated on a 16% poly-
acrylamide gel, using tricine as a trailing ion instead of tris-glycine 
[20]. This system has an improved resolution for low molecular 
weight molecules . Gels were blotted on PVDF membranes or sliced 
in order to elute SKALP from the gel. To this end, 2-mm slices of 
SDS-gel were extracted for 30 min in buffer and assayed as described 
above. Protein staining on PVDF membranes was performed with 
ami do black according to standard procedures. Using a rabbit anti-
serum raised against highly purified SKALP from psoriatic scales, 
immunologic detection of proteins was performed as described be-
fore [13] . A polyclonal antiserum against ALP /SLPI was a kind gift 
of Dr. J .A. Kramps, Department ofPulmonology, Academic Hospi-
tal Leiden, The Netherlands. 
RESULTS 
Measurement of Anti-Elastase Activity in Urine In prelimi-
nary experiments we noticed that in urine from psoriatic patients 
variable amounts of anti-elastase activity could be demonstrated, 
and even small amounts of free elastase activity were occasionally 
found. Due to the complex situation of both elastase and inhibitor 
being present, a direct quantification of the amount of biologically 
active inhibitor was not possible . Therefore we developed a proto-
col for measurement of the total (latent plus free) anti-elastase activ-
ity in urine, by making use of the differential heat stability of elas-
tase and inhibitor. By boiling the urine for a short period, elastase is 
den.atured and heat-stable inhibitors are released from the enzyme-
inhibitor complex. Figure 1 shows an example of urine from a 
psoriatic patient that contained a small amount of free elastase activ-
ity. When the urine was boiled and samples were drawn at various 
time intervals, it was found that the elastase activity disappeared 
(within 1 min) and that anti-elastase activity was released. The 
inh.ibition curves of urine samples taken at t = 0, 1,2,4, and 8 min 
as depicted in Fig 1, show that 2 min boiling gives an optimal 
recovery of heat-stable anti-elastase activity. 
Using this protocol, heat-stable anti-elastase activity in the urine 
of 33 psoriatic patients and 10 healthy controls was measured as 
described in the Materials and Methods section. Table I shows the 
values of all patients and controls. Most of the psoriatic patients 
showed urinary anti-elastase activity. In urine of healthy controls 
anti-elastase activity was undetectable in all but one cases. 
Cbaracterization of Urinary Anti-Elastase Activity In order 
to investigate its possible identity to SKALP, the urinary anti-elas-
tase activity was further characterized by its behavior on a PBE 94 
chromatofocusing column. Figure 2 shows that most of the activity 
elutes in the void volume, indicating that it is a cationic molecule, 
very much like SKALP [13]. In the fractions collected after regenera-
tion of the column with 1 M NaCI, only a small amount (less than 
5%) of inhibitor was eluted. Determination of the dissociation con-
stant K; was carried out with the pooled fractions of the void volume 
of the chromatofocusing experiment, in which the highest anti-
elastase activity was measured. Figure 3 shows an Easson-Stedman 
plot. The slope of the lines obtained for SKALP from urine and 
scales yields a similar K j of approximately 2-1O-11M, which is in 
accordance with previous findings [12,13] . 
SDS-P AGE and Western Blotting The partially purified inhib-
itor preparation was subjected to SDS-PAGE. The gel was cut in 
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Table I. Anti-Elastase Activity in Urine of Psoriatic Patients (n = 33) and Controls (n = 10) in Units of SKALP per mla 
Psoriatics Controls 
Sex Age SKALP Sex Age SKALP Sex Age SKALP 
1. f 66 880 18. f 34 1408 1. m 31 ND 
2. f 26 1568 19. m 60 ND 2. m 28 ND 
3. m 49 6656 20. m 29 212 3. m 36 ND 
4. m 40 816 21. f 47 752 4. m 28 ND 
5. m 42 ND 22. m 65 768 5. m 58 ND 
6. m 66 456 23. f 67 232 6. f 25 432 
7. m 35 416 24. f 31 312 7. m 44 ND 
8. m 38 ND 25. f 77 ND 8. m 33 ND 
9. m 50 352 26. f 80 376 9 . f 36 ND 
10. f 86 668 27. m 67 ND 10. f 57 ND 
11. m 49 ND 28. m 76 424 
12. m 23 704 29. f 36 232 
13. f 68 424 30. f 27 1856 
14. f 23 ND 31. f 24 1376 
15. f 24 416 32. f 18 456 
16. m 18 288 33. m 27 400 
17 . f 32 204 
• Inhibitory activity was measured as described in the Matedals andMethods section. Values below the detection limit of200 units per ml urine are marked with ND (non detectable). 
A statistically significant difference in inhibitory activiry between psoriatics and controls was found (p < 0.002, Mann-Whitney U-test) . 
2-mm slices and assayed for anti-elastase activity as can be seen in 
Fig 4. Only one peak of activity was found, corresponding with a 
molecular weight of about 11 kDa, a value that was previously 
found for SKALP purified from psoriatic scales. In addition, gels 
were blotted on PVDF-membranes, which were used for protein 
staining and for immunostaining. As shown in Fig 5, the partially 
purified preparation obtained by chromatofocusing contains several 
low molecular weight bands, one of which coincides with the band 
of anti-elastase activity found in gel slices (see Fig 4). Using a poly-
clonal antiserum raised against highly purified SKALP from psori-
atic scales, two bands were stained. The high molecular weight 
band coincides with the 11-kDa band of anti-elastase activity, the 
low molecular weight band probably represents an inactive break-
down product. A polyclonal antiserum against ALP /SLPI that is a 
related proteinase inhibitor with similar properties was tested in 
units (x 1000) 
30 
20 
10 
8 11 16 21 26 
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Figure 2. Chromatofocusing of concentrated urine. PBE 94 was used, 
eluated with 0.025 M ethanolamine (pH 9.4). One milliliter of sample was 
applied (open arrow), after which the column was regenerated with 1 M NaCI 
(solid arrow). Anti-elastase activity was measured in all fractions and ex-
pressed as units per fraction (bars) . As can be seen from the elution profile 
(solid line; absorbance 280 nm; arbitrary scale) most of this anti-elastase 
activity elutes in the void volume, containing the material that does not bind 
to the column. 
parallel. Both the anti-ALP /SLPI antiserum and preimmune rabbit 
serum (control for anti-SKALP) were negative. 
DISCUSSION 
The structural integrity of human skin is at risk during acute inflam-
matory reactions when activated phagocytes (PMN, monocytes, 
macrophages) invade the papillary dermis and epidermis, e.g., in 
psoriasis [21]. These inflammatory cells are known to secrete large 
amounts of proteinases that can damage extracellular matrix pro-
teins, basement membranes, and desmosomal structures [1,9,22] . 
Normal human epidermis contains very little inhibiting activity 
against elastase, one of the major PMN-derived proteinases. How-
ever, we have recently shown that in a number of inflammatory skin 
diseases large amounts of epidermal anti-elastase activity can be 
found, in particular in psoriasis [12]. The major source of the anti-
elastase activity could be ascribed to a cationic, low molecular 
weight protein that was given the acronym SKALP [13]. In view of 
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Figure 3. K; determination of SKALP. Easson-Stedman plot of l /a (a = 
fractional activity) against Ij(l-a) (I = inhibitor concentration). See also 
Materials and Methods section. The slope of the line yields the apparent K;. 
Open triatlgles: partially purified SKALP from urine; opef! squares: SKALP 
purified from scales. 
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Figure 4. Anti-elastase activity eluted from an SDS gel. Partially purified 
urinary elastase inhibitor was electrophoresed under non-reducing condi-
tions. The SDS gel was cut in 2-mm slices and extracted in CTAB. The 
amount of anti-elastase activity recovered from the gel slices is given in units. 
The positions of marker proteins are indicated with arrows (kDa) . 
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Figure 5. Western blotting of partially purified urinary elastase inhibitor. 
In lane 2 distinct bands were stained with a polyclonal rabbit antiserum raised 
against SKALP from psoriatic scales. Preimmune serum (lane 3) and a rabbit 
polyclonal antiserum against ALP /SLPI (lane 4) were used as a control, the 
latter to exclude ALP /SLPI as the cause of the anti-elastase properties of the 
urine; both lane3 and 4 were negative. A positive control (10 ng recombinant 
ALP /SLPI) for the rabbit polyclonal antiserum against ALP /SLPI is shown 
in lane 5. Total protein staining of the urinary SKALP sample with amidob-
lack is shown in lane 6, and molecular weight markers (kDa) in lanes 1 and 7. 
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its physico-chemical properties, SKALP will easily cross the basal 
lamina, penetrate the connective tissue, and reach the circulation. 
Because small cationic proteins are readily excreted in the urine, we 
investigated whether SKALP could be found in urine from psoriatic 
patients . In this paper we show that considerable amounts of anti-
elastase activity can be found in urine from most of the psoriatic 
patients, whereas urine from healthy controls is usually negative. 
The anti-elastase activity could be ascribed to SKALP, based on 
biochemical and immunologic criteria. The urinary anti-elastase 
activity as measured in our assay was not due to ai-proteinase inhibi-
tor (data not shown). In addition we could exclude that the activity 
was due to ALP /SLPI, which is a proteinase inhibitor that shows 
structural and functional similarity to SKALP. 
Interestingly, in some of the patients we found low levels of free 
elastase activity in the urine, whereas SKALP activity was undetect-
able. SKALP activity could be unmasked by boiling the urine, 
which destroys elastase activity, as shown in Fig 1. This finding 
emphasizes the importance of SKALP as a physiologically relevant 
elastase inhibitor. 
The presence of SKALP in urine strongly suggests (but does not 
prove) that it is from epidermal origin. Immunohistologic and func-
tional studies indicate that the keratinocytes are the source of epi-
dermnal SKALP; inflammatory cells were found to be negative 
(data not shown). Unfortunately we have no assay at the moment 
that allows quantification of immunoreactive SKALP. Once a 
SKALP-specific enzyme-lined immunosorbent assay is available, 
the presence in plasma could be established, to link the presence in 
epidermis and urine. This would, in addition, allow a more sensitive 
measurement of SKALP and its breakdown products in urine. Pre-
liminary results of measurement of biologically active SKALP in 
urine suggest a relationship between disease severity and urinary 
SKALP levels. 
Future research will be aimed at developing sensitive, discrimina-
tive assays for detection of urinary SKALP (active and inactive frag-
ments) . This might yield a useful, noninvasive, quantitative mea-
sure for disease activity. 
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ROTHMAN CLUB MEETING REPORT 
Prepared by R.D. Sontheimer, M.D. 
Drs . David Woodley, Robert Swerlick, and Rick Sontheimer, the current officers of the 
Stephen Rothman Club, hosted this year's an.nual meeting at the A.W. Ha7ris Faculty Club at 
the University of Texas Southwestern Medical Center on Tuesday evemng, December 10, 
1991. 
This organization was formed in the 1950s by Drs. Thomas Fitzpatrick and Aaron Lerner as a 
study club comprised of young investigators in dermatology who got together at the time of the 
American Academy of Dermatology's annual meeting to discuss current scientific issues of 
common interest (personal communication, Dr. Thomas Fitzpatrick, December 10, 1991). 
Membership was initially limited to those academic dermatologists under the age of 45 years. 
Because of their respect for his work, Dr. Stephen Rothman was the first individual above that 
age invited to attend the meeting. This study club was subsequently designated as the Stephen 
Rothman Club following Dr. Rothman's death in 1963. 
The goals of this organization have since evolved somewhat. In addition to honoring the 
memory of Dr. Rothman, the Club is now also dedicated to fostering interest in investigative 
dermatology by bringing together inquisitive young people (residents, fellows, a~d junior 
faculty) in an informal atmosphere of camaraderie and good cheer. 
Approximately 80 individuals attended this year's annual meeting. Following the meal, Dr. 
Daniel P . McCauliffe, Assistant Professor of Dermatology at the University of North Carolina 
School of Medicine, gave a stimulating presentation of his work in the area of Ro/SS-A 
autoantigen gene characterization that lucidly illustrated the power of the techniques of mod-
ern molecular biology. 
The Rothman Club is a non-profit organization whose activities are supported predomi-
nately by donations from industry. The officers of this organization would like to take this 
opportunity to thank the following corporations whose unconditional generosity is greatly 
appreciated. 
Patrons The Collagen Corporation, Hoechst-Roussel Pharmaceutical, Inc.; Ortho Pharma-
ceutical Corporation; and SmithKline Beecham. 
Sponsors Glaxo Dermatology Products; Owen/ Galderma; Stiefel Laboratories, Inc.; Syntex 
Laboratories, Inc.; and Westwood-Squibb. 
